Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones

Cocrystal Pharma, Inc.

Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.
Expects to report topline results from Phase 1 multiple-ascending cohorts for oral norovirus/coronavirus protease inhibitor CDI-988 in late 2024 or early 2025.
Management will present at Virtual Investor Summit Microcap Forum on Aug 20, 2024, and H.C. Wainwright Conference starting Sept 9, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.